S'abonner

Complications After Radical Prostatectomy or Radiotherapy for Prostate Cancer: Results of a Population-based, Propensity Score–matched Analysis - 01/03/15

Doi : 10.1016/j.urology.2014.11.037 
Christopher J.D. Wallis a, Sender Herschorn a, Refik Saskin b, Jiandong Su b, Laurence H. Klotz a, Michelle Chang a, Girish S. Kulkarni c, Yuna Lee d, Ronald T. Kodama a, Steven A. Narod e, Robert K. Nam a,
a Division of Urology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada 
b Institute of Evaluative Clinical Sciences, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada 
c Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada 
d Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada 
e Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada 

Address correspondence to: Robert K. Nam, M.D., M.Sc., 2075 Bayview Avenue, Room MG-406, Toronto, Ontario, Canada M4N 3M5.

Abstract

Objective

To assess rates of treatment-related complications after radical prostatectomy or radiotherapy monotherapy, using propensity score matching to account for baseline differences between these patient populations.

Methods

On the basis of a population-based study of men undergoing surgery or radiotherapy for prostate cancer in Ontario between 2002 and 2009, we undertook a propensity score–matched analysis including age, comorbidity, and year of treatment to assess treatment-related complication end points. These included hospital admission; urologic, rectal, or anal procedures; open surgeries; and secondary malignancies.

Results

From the original cohort of 32,465 patients, 15,870 (48.9%) had surgery and 16,595 (51.1%) had radiation. Propensity score matching produced 8797 pairs (17,594 patients). Among these, when compared with patients treated with surgery, those treated with radiation experienced fewer admissions to hospital (hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.78-0.92) and urologic procedures (HR, 0.50; 95% CI, 0.46-0.53) at year 1 but higher rates at year 3 (HR, 5.65; 95% CI, 4.61-6.91 and HR, 1.86; 95% CI, 1.62-2.13, respectively) and year 5. Although there was no significant difference in open surgeries at year 1, patients undergoing radiotherapy were at higher risk by year 3 (HR, 2.06; 95% CI, 1.23-3.47) and this rose by year 5. Over the study period, patients undergoing radiotherapy experienced more rectal-anal procedures (HR, 2.64; 95% CI, 2.37-2.95) and were diagnosed with more secondary malignancies (HR, 2.44; 95% CI, 1.16-5.14). Direct matching produced similar results.

Conclusion

From a propensity score–matched analysis, we found that patients undergoing radiation therapy for prostate cancer had higher rates of long-term complications in all 5 categories studied than patients undergoing surgery.

Le texte complet de cet article est disponible en PDF.

Plan


 Financial Disclosure: This study was solely funded by the Ajmera Family Chair in Urologic Oncology awarded to Robert K. Nam. The funding source had no role in any part of the study.
 Funding Support: This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Jiandong Su and Refik Saskin had access to the raw data. Robert K. Nam and Christopher J.D. Wallis had full access to all the data and take responsibility for the integrity of the data and the accuracy of the data analysis.


© 2015  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 85 - N° 3

P. 621-628 - mars 2015 Retour au numéro
Article précédent Article précédent
  • Effect of Finasteride on Serum Androstenedione and Risk of Prostate Cancer Within the Prostate Cancer Prevention Trial: Differential Effect on High- and Low-grade Disease
  • Ashraful Hoque, Song Yao, Cathee Till, Alan R. Kristal, Phyllis J. Goodman, Ann W. Hsing, Catherine M. Tangen, Elizabeth A. Platz, Frank Z. Stanczyk, Juergen K.V. Reichardt, Adrie vanBokhoven, Marian L. Neuhouser, Regina M. Santella, William D. Figg, Douglas K. Price, Howard L. Parnes, Scott M. Lippman, Christine B. Ambrosone, Ian M. Thompson
| Article suivant Article suivant
  • Editorial Comment
  • Ted A. Skolarus

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.